ArticleRetinal cases & brief reports2025
MANAGEMENT OF PERIFOVEAL EXUDATIVE VASCULAR ANOMALOUS COMPLEX.
Article in Retinal cases & brief reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report a case of a patient with perifoveal exudative vascular anomalous complex (PEVAC) and to analyze morphologic and vascular changes by optical coherence tomography (OCT) and OCT angiography (OCTA) before and after treatment. MATERIALS AND
methodsThe authors reported a case that received multiple treatments for unresponsive effect to repeated aflibercept intravitreal injections, subthreshold micropulse laser therapy duty cycle 5%. At last, the focal full-dose yellow laser was performed.
resultsA 57-year-old male patient presented with best-corrected visual acuity (BCVA) of 20/50 in his right eye (RE). The fundoscopic evaluation, structural OCT, and OCTA deposed for a diagnosis of PEVAC. The patient underwent three aflibercept intravitreal injections in the RE. Because no changes were detected, the authors opted for multiple sessions of yellow subthreshold micropulse laser therapy duty cycle 5%; however, no signs of regression were registered. Only after a full-dose yellow laser, signs of edema regression were observed. Structural OCT B-scan showed complete restoration of retinal profile, in the absence of any intraretinal or subretinal fluid and PEVAC lesion, whereas the OCTA showed a slight flow deficit at the previous lesion site. CONCLUSION AND IMPORTANCE: The PEVAC treatment is still unknown. In their experience, the authors reported a case of multiple treatments for unresponsive effect to aflibercept intravitreal injections, subthreshold micropulse laser therapy duty cycle 5%. The focal full-dose yellow laser was the only effective treatment in this patient. The authors proposed the management to share the heterogeneous response at PEVAC entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.